All AbMole products are for research use only, cannot be used for human consumption.
Leukadherin-1 is a allosteric activator of CD11b/CD18. Leukadherin-1 increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50 = 4 μM). Leukadherin-1 decreases leukocyte motility and transendothelial migration; reduces inflammation. Leukadherin-1 also activates complement receptor 3 (CR3), and promotes CR3-dependent leukocyte adhesion to fibrinogen-coated surfaces. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.
Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).
| Cell Experiment | |
|---|---|
| Cell lines | NK cells |
| Preparation method | NK cell stimuli (where used) were added as follows: (1) Syk inhibitor (1 μM), (2) Leukadherin-1 or dimethylsulphoxide (DMSO) (vector control) (7.5 μM). Shown to induce ∼82% of maximum response with negligible off-target effect, (3) anti-CD210 or isotype control (5 µg/ml), (4) 30-45 min after Leukadherin‐1 NK cells were stimulated with combinations of IL-12 (10 ng/ml), IL-15 (30 ng/ml) or IL-18 (10 ng/ml): either IL-12 + IL-15 or IL-12 + IL-18. Monocytes were stimulated using pam3csk4 (TLR-2 agonist, 300 ng/ml) or R848 (TLR-7/8 agonist, 2 µg/ml). Supernatants were stored at −80ºC for < 1 month before quantification. To exclude non-specific Leukadherin-1-mediated cytotoxicity, cell viability is assessed at 24 h using the CellTitre-Glo reagent. |
| Concentrations | 7.5 μM |
| Incubation time | 30-45 min |
| Animal Experiment | |
|---|---|
| Animal models | Male C57BL/6J (H-2b) and Balb/cJ (H-2d) mice |
| Formulation | cyclosporine |
| Dosages | 1 mg/kg or 2.5 mg/kg |
| Administration | i.v. or i.p. |
| Molecular Weight | 421.49 |
| Formula | C22H15NO4S2 |
| CAS Number | 344897-95-6 |
| Solubility (25°C) | DMSO 4 mg/mL (with gentle warming) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Integrin Products |
|---|
| Volociximab
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| GSK 3008348 hydrochloride
GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist. |
| HSDVHK-NH2
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
| LDV
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
| Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
